To evaluate the safety and efficacy of transurethral enucleation and resection of prostate with bipolar plasma rod electrode(TUERP-BPRE) in the treatment of benign prostatic hyperplasia (BPH).

The clinical data of 157 BPH cases treated by operation from May 2018 to December 2019 were analyzed retrospectively, including 92 cases in TUERP-BPRE group and 65 cases in TURP Group. The perioperative data and follow-up results in the 3-month postoperation were compared between the two groups.

There was no significant difference in preoperative baseline characteristics between the two groups. The operation time [(60.1±19.6) min vs (67.7±9.1) min], decrease of hemoglobin [(6.1±2.8) g/L vs (7.7±1.5) g/L], bladder irrigation time [(8.1±1.6) h vs (9.1±2.0) h], catheterization time [(4.5±0.7) d vs (4.9±0.8) d] and the duration of hospitalization [(5.3±0.8) d vs (5.7±0.8) d] were significantly lower in TUERP-BPRE group than that in TURP group. The IPSS, QOL, RUV and Qmax of the two groups in the 3-month postoperation were significantly improved than preoperation, while there was no significant difference between the two groups. Moreover, in TUERP-BPRE group, the incidences of electrolyte disturbance (6.5% vs 21.53%) , delayed hematuria (6.5% vs 23.1%) , temporary urinary incontinence (5.4% vs 18.5%) and retrograde ejaculation (2.2% vs 15.4%) were significantly lower than that in TURP group.

The efficacy of TUERP-BPRE and TURP were similar, while the former technique provides shorter operation time, less blood loss, quicker postoperative recovery and fewer complications, which is worthy of clinical application.